# US 2017/0281559 A1 · Stealth, targeted nanoparticles (stn) for oral drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281559 A1
- Document ID: US20170281559A1
- Status: Published application
- Kind: A1
- Application number: 15/514,333
- Filed: 2015-09-22
- Published: 2017-10-05
- Earliest claimed: 2014-09-25
- Inventors: Manu CHAUDHARY
- Web page: https://patentgrep.com/patent/US20170281559A1

## CPC

- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4164: 1,3-Diazoles
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 38/05: Dipeptides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/6939: {the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

## Claims

### Claim 1

A composition for targeted delivery of poorly bioavailable therapeutic agents comprising of stealth targeted nanoparticles, wherein said stealth targeted nanoparticles comprise of:
i) a non lipidic polymer matrix, comprising of at least one stealth polymer and at least one polysaccharide;
ii) a non protein target agent/ligand;
iii) one or more than one poorly bioavailable therapeutic agent; wherein the weight ratio of said polymer to said polysaccharide is 1:10 to 10:1; wherein said target ligand and said poorly bioavailable therapeutic agent are physically
entrapped inside the non lipidic polymer matrix without conjugation or covalent bond;
wherein the composition of said stealth targeted nanoparticles when administered, form smaller nanoparticles of size <20 nm; wherein the said smaller nanoparticles increase bioavailability of said poorly bioavailable therapeutic agent to >70%; wherein said composition is administered orally in the subjects of need.

### Claim 2 (depends on 1)

The composition of claim 1, wherein bioavailability of said poorly bioavailable therapeutic agents are increased by 70-90%.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said stealth polymer is selected from a group comprising of, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polyacrylamide (Pam), polyethylene glycol (PEG) and PEG-based copolymers such as poloxamers, poloxamines, polysorbates, PEG derivatives, PEG-2000 to 20000, monomethoxy PEG-2000 to 20000, monomethoxy PEG methylether, d-PEG, biotinylated-PEG, Hydrophilic poly(oxazoline)(PMOXA), poly(2-ethyl-2-oxazoline), poly (hydroxyethyl-asparagine) (PHEA), N-(2-hydroxypropyl)methacrylamide (HPMA), poly(sulfobetaine), poly(carboxybetaine), hyperbranched polyglycerol, Poly(hydroxymethylethylenehydroxymethylformal), PEG-succinimidyl-succinate, NHS-monomethoxy PEG butanoic acid, NHS-monomethoxy PEG butanoic acid-lysine, monomethoxy PEG aldehyde (MW 20000 Da), PEG p-nitrophenyl carbonate ester, 20 kDa linear monomethoxy-PEG aldehyde and the like.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said polysaccharide agent is selected from a group comprising of guar gum, gum arabic, gum tragacanth, larch gum, gum karaya, locust bean gum, agar, alginates, carageenan, pectins, starch, c-starch, xanthan gum, succinoglucan, pullulan chitin, chitosan, polysialic acid, hyaluronic acid, heparin, starch/acrylic acid graft copolymer, complex carbohydrates, dextran and the like.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the non protein targeting agent/ligand is selected from a group comprising of small molecule such as a neurotransmitter, hormone, a pharmaceutical drug, vitamin, anti oxidants, toxin, or parts of the outside of a virus or microbe such as but not limited to glucose-6-phosphate, mannose, palmitate, myristate, geranylgeraniol, farnesol, dolichol, cholesterol, ubiquinone (coenzyme Q 10), folic acid, biotin, cyanocobalamine, hydoxycobalamine, sterol, bile acids, squalene, wheat germ aglutinin, pyridoxal phosphate, tocopherol, lipidic growth factor, glucosamine, glycosamine, glycolipids, and the like.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the said non protein targeting ligand is polar in nature, wherein ligand moves to surface due to blooming.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the poorly bioavailable therapeutic agents is a drug, a nutraceuticals, a diagnostic agent, a salt thereof, an isomer thereof, a derivative thereof, or a mixture thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein drug is selected from the group of small molecules consisting of antibiotics, antivirals, anti osteoporosis, anti arrhythmic, ACE inhibitors, antihistamines, anticancer, anti fungal, diuretic, anthelmintic, anti-tubercular, anti-rheumatoid, anti-ulcer drugs, immunosuppressant, BCS class III, BCS class IV drugs and mixture thereof.

### Claim 9 (depends on 7)

The composition of claim 7, wherein drug is antibiotic and is selected from the group consisting of beta lactam antibiotic such as cephalosporins, carbapenems, cephamycin, monobactams and penicillins alone or in a combination with beta-lactamase inhibitor, polymixin, sulphonamides, tetracyclines, aminoglycosides, lincosamides, streptogramins, ketolides, glycylcyclines, phenicols, oxazolidinones, ansamycins, glycopeptide, lipopeptides, cyclic lipopeptides, fluoroquinolones, imidazole, fosfomycins, oxalidinones, macrolides, anti metabolites, furanes or pharmaceutically acceptable salts, isomers and derivative thereof.

### Claim 10 (depends on 9)

The composition of claim 9, wherein drug is selected from the group consisting of ceftriaxone, cefepime, ceftazidime, cefuroxime, cefexime, cefpodoxime, cefaclor, cefoperazone, cefadroxil, ceftibuten, cefdinir, cefditoren, ceftizoxime, cefamandole, cefazoline, cefonicid, cefoxitin, cefprozil, cephalexin, cephapirin, ceftobiprole, ceftolozane, ceftaroline, cephradine, meropenem, doripenem, eratpenem, panipenem, tebipenem, sanfetrinem, tomopenem, biapenem along with amikacin, etimicin, gentamicin, tobramycin, polymixin, colistin, vancomycin, teicoplanin, dalbavancin, oritavancin, telavancin, azithromycin, erythromycin, roxithromycin, clindamycin, lincomycin, dicloxacillin, ampicillin, clarithromycin, amoxicillin, ampicillin, sulbactam, tazobactam, clavulanic acid, avibactam, relebactam, RPX709, NXL104, AVE1330A or pharmaceutically acceptable salts, isomers, derivative thereof, and mixtures thereof.

### Claim 11 (depends on 10)

The composition of claim 10, wherein drug is combination of beta lactam antibiotic along with one or more of co drug as beta lactamase inhibitor; wherein the said beta-lactam antibiotic is selected from a group comprising of ceftriaxone, cefepime, ceftazidime, cefuroxime, cefexime, cefpodoxime, cefaclor, cefoperazone, cefadroxil, ceftibuten, cefdinir, cefditoren, ceftizoxime, cefamandole, cefazolin, cefonicid, cefoxitin, cefprozil, cephalexin, cephapirin, ceftobiprole, ceftolozane, ceftaroline, cephradine or a pharmaceutically acceptable salt thereof and the said co-drug is beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, avibactam, relebactam, RPX709, NXL104, AVE1330A or a pharmaceutically acceptable salt, isomers, derivative thereof.

### Claim 12 (depends on 10)

The composition of claim 10, wherein drug is combination of carbapenem antibiotic along with one or more of beta lactamase inhibitors; wherein the said carbapenem drug is selected from a group comprising of meropenem, etrapenem, doripenem, panipenem, tebipenem, sanfetrinem, tomopenem, biapenem or a pharmaceutically acceptable salt thereof and the said beta-lactamase inhibitor selected from group comprising of sulbactam, tazobactam, clavulanic acid, avibactam, relebactam, RPX709, NXL104, AVE1330A or a pharmaceutically acceptable salt, isomer, derivative thereof.

### Claim 13 (depends on 9)

The composition of claim 9, wherein drug is combination of carbapenem antibiotic along with one or more of antibiotic drug whose mechanism of killing bacteria is different from that of carbapenems; wherein the said carbapenem drug is meropenem, doripenem, ertapenem, panipenem, tebipenem, sanfetrinem, tomopenem, biapenem or a pharmaceutically acceptable salt thereof and the said second antibiotic is one or more of drug or pro drug of aminoglycoside, glycopeptide, lipopeptide, polymixin, quinolone, imidazole or a pharmaceutically acceptable salt, isomer, derivative thereof.

### Claim 14 (depends on 9)

The composition of claim 9, wherein drug is combination of cephalosporin antibiotic along with one or more of second antibiotic drug whose mechanism of killing bacteria is different from that of cephalosporins; wherein the said cephalosporin drug is ceftriaxone, cefepime, ceftazidime, cefuroxime, cefexime, cefpodoxime, cefaclor, cefoperazone, cefadroxil, ceftibuten, cefdinir, cefditoren, ceftizoxime, cefamandole, cefazolin, cefonicid, cefoxitin, cefprozil, cephalexin, cephapirin, ceftobiprole, ceftolozane, ceftaroline, cephradine or a pharmaceutically acceptable salt thereof and the said second antibiotic is one or more of drug or pro drug of aminoglycoside, glycopeptide, lipopeptide, polymixin, quinolone, imidazole or a pharmaceutically acceptable salt, isomer, derivative thereof.

### Claim 15 (depends on 8)

The composition of claim 8, wherein drug is anticancer and is selected from the group comprising of cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide, plant alkaloids including vinca alkaloids such as vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxins such as etoposide and teniposide, taxanes such as docetaxel, paclitaxel, topoisomerase inhibitors such as irinotecan and topotecan, cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, dactinomycin, cytarabine, bortezomib, gemcitabine, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, fludarabine, clatribine, methotrexate, 5-flurouracil, amscrine, cladribine, carmustine plicamycin, mitomycin, pemetrexate capecitabine, dasatinib, erlotinib, fludarabine, imatinib, lapatinib, nilotinib, sorafenib, sunitinib, thalidomide, 9-nitrocamptothecin, curcumin, exemestane, mitotane, raloxifene, emodin, methotrexate, tamoxifen, benzyl isothiocyanate, melphalan, meso-tetraphenyl porphine, a-mangostin, quercetin, epigallocatechin gallate, 10-hydroxycamptothecin, thymopentin, rapamycin, altretamine, anagrelide, anastrazole, bexarotene, bicalutamide, finasteride, gefitinib, hydroxycarbamide, ibandronic acid, imatinib, lapatinib, lenalidomide, letrozole, mercaptopurine, nilutamide, procarbazine, raloxifene, rubitecan, sobuzoxane, sunitinib, tamibarotene, tamoxifen, temozolomide, thalidomide, thioguanine, toremifene, treosulfan, vorinostat or a pharmaceutically acceptable salt, isomer, derivative thereof.

### Claim 16 (depends on 8)

The pharmaceutical composition of claim 8, wherein drug is immunosuppressant and selected from the group comprising of azathioprine, cyclosporine, daclizumab, mycophenolate mofetil prednisone, sirolimus, tacrolimus, everolimus, basiliximab muromonab CD3 or a pharmaceutically acceptable salt, isomer, derivative thereof.

### Claim 17 (depends on 8)

The composition of claim 8, wherein drug is anti inflammatory and selected from the group comprising of celecoxib, diclofenac, diflunisal, etodolac fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin or a pharmaceutically acceptable salt, isomer, derivative thereof.

### Claim 18 (depends on 7)

The composition of claim 7, wherein said therapeutic agent is nutraceutical and is selected from a group comprising of vitamins, anti oxidants, dietary minerals, essential elements, proteins, herbal extracts, herbal supplement, and any other agent used with known poor bioavailability of synthetic or natural origin and the like.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the said stealth polymer is PEG, preferably PEG 20,000; wherein the said polysaccharide is dextran, preferably dextran 40 kDa; wherein the target ligand is a vitamin in range of 0.01 mg to 10 mg and is preferably folic acid; wherein the said therapeutic agent is poorly bioavailable drug/nutraceutical; wherein the weight ratio of PEG to Dextran is 1:10 to 10:1, preferably 1:5 to 5:1;
wherein the ratio of said poorly bioavailable therapeutic agent to said ligand appended polymer matrix is 1:1 to 1:10, preferably 1:4;
wherein the said ligand and the said therapeutic agent are physically entrapped in polymer matrix, without conjugation/covalent bond to form stable, stealth targeted nanoparticles of size <1OOOnm;
wherein the said nanoparticles swell and burst after oral administration to form smaller nanoparticles of size <20 nm to improve cumulative bioavailability to >100% of said therapeutic agent.

### Claim 20

A method of preparation of a composition for targeted delivery of poorly bioavailable therapeutic agent comprising of stealth targeted nanoparticles, said method comprising the steps of: i. preparing a semi-inter-penetrating-network of a stealth polymer, a polysaccharides and a targeting ligand by dissolving polymer and polysaccharide in a fixed weight ratio with targeting ligand in aqueous solution; ii. adding the said poorly bioavailable therapeutic agent or a mixture of agents to above semi inter penetrating network and mixing under inert atmosphere, for a few minutes to form a clear solution;
iii. heating above solution of stage ii between 120 to 170 degree celcius to harden the polymer matrix during spray drying to obtain stealth targeted nano particles of size <1000 nm.

### Claim at position 21

21-25. (canceled)
